Summit thinks twice about USD 200m public offering citing adverse market conditions

Summit Therapeutics Inc. (Nasdaq: SMMT) on June 12, 2026, disclosed its decision to withdraw an underwritten public offering proposed just two days previously, citing adverse market conditions. The cancellation means no securities were sold and no proceeds were raised, leaving the company to rely on existing resources — including an expanded at-the-market facility — to fund its ivonescimab development program.

The withdrawal is notable given Summit's active capital-raising history. Since licensing ivonescimab (SMT112) from China-based Akeso in December 2022, Summit has completed a USD 200 million public equity offering in June 2024 and a USD 500 million private placement in 2025, in addition to expanding its ATM facility by approximately USD 360 million in August 2025. The failed June 2026 offering suggests that market conditions at the time of launch did not support the pricing or size management sought, a dynamic that has affected multiple clinical-stage oncology companies in recent quarters.

Summit is built almost entirely around ivonescimab, a bispecific antibody that simultaneously blocks PD-1 and VEGF signaling. The dual-blockade mechanism is designed to combine checkpoint inhibition with anti-angiogenic activity in a single molecule, potentially offering advantages over sequential or combination use of separate agents. Akeso, which retains rights in China and select other markets, has reported statistically significant progression-free survival data for ivonescimab versus pembrolizumab in PD-L1-high non-small cell lung cancer — results that generated substantial investor interest in Summit's licensed territories, which cover the US, Canada, Europe, Japan, Latin America, the Middle East, and Africa following a June 2024 territory expansion.

Summit is running the HARMONi-A Phase III trial evaluating ivonescimab in combination with chemotherapy in EGFR-mutant NSCLC, and additional Phase III studies are underway or planned across other NSCLC subpopulations. The company has no approved products and no near-term revenue, making continued capital access a central strategic consideration. Competitors developing PD-1/VEGF or similar bispecific approaches include AstraZeneca, whose reported advanced licensing discussions with Summit — valued at up to approximately USD 15 billion according to media reports from mid-2025 — have not resulted in a disclosed agreement.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article